Cancer Research. Peptide Innovations in. Neo-Epitope Analysis Immunotherapy Cancer Proteomics Enzyme Profiling Epigenetics

Transcription

1 Peptide Innovations in Cancer Research Neo-Epitope Analysis Immunotherapy Cancer Proteomics Enzyme Profiling Epigenetics Innovative Peptide Solutions

2 Neo-Epitope Analysis Neo-epitopes encoded by the mutanome can be used to direct and enhance the patient s immune response to the tumor. Quick production of neo-epitope libraries is necessary to select effective neo-epitopes for immunotherapy development. Immunotherapy Many immunological cell therapy approaches use peptides to produce antigen-specific cells and to monitor stimulated immune responses. Our regulated ISO and GxP peptide preparations support all development phases. Epigenetics & Histones in Cancer Histone modifications regulate histone interaction with DNA and proteins, affecting diverse biological processes. Ab nor mal histone modification patterns are associated with human malignancies. To study these patterns we offer histone peptide libraries, peptide microarrays and ELISA. Cancer Proteomics Changes in protein expression patterns measured via mass spectrometry against peptide standards are used to identify and quantify biomarkers to develop cancer therapies and diagnostics. Enzyme Profiling Kinases, sirtuins and other enzymes play a key role in tumorgenesis and are targets for cancer therapy. Identify substrates and enzyme profiles with JPT s enzyme profiling tools.

3 Cellular Immunity PepMix Peptide Pools Overlapping peptide pools, matrix pools or neo-epitope pools representing entire antigens or immune relevant epi tope collections for stimulation of antigen-specific T cells in T cell assays e.g. ELISPOT or flow cytometry. PepTrack Peptide Libraries Customized peptide libraries, optimized for the use in T cell assays such as ELISPOT or ICS for fast provision of overlapping peptides and neo-epitopes enabling epitope mapping and qualification. GxP Peptides GxP Peptides are produced in a stringent production environment beyond ISO 9001:2015 regulations for cellular therapy including adoptive T cell transfer and dendritic cell pulsing. We offer a wide spectrum of analytical tests to meet your regulatory requirements. MHC Multimers MHC Multimers present MHC-peptide comlexes that are very efficient for detection, enumeration and isolation of antigen-specific T cells in fluid cell samples (PBMC, blood) by flow cytometry. Visit us online at or contact us at peptide@jpt.com PepMix Peptide Pools represent antigens as synthetic overlapping pep tides to be used for antigen-specific stimulation in functional T cell assays such as ELISPOT and flow cytometry. Peptide synthesis Pooling T cell assay

4 Humoral Immunity PepStar Peptide Microarrays Peptide Microarrays present overlapping peptide scans, neo-epitopes and more for incubation with patient samples (serum, blood) or antibodies. Peptide ELISA Customized peptide ELISA plates enable mapping of epitopes, definition of protein interaction sites or validation of microarray results. Modular Seromarker Discovery Service We offer a modular assay service using our PepStar and Peptide ELISA platforms. Contact us for further information! Proteomics Peptide Standards for Mass Spectrometry Isotope labeled SpikeTides Peptides and SpikeMix Peptide Pools for mutiplexed biomarker discovery and quantification. Enzyme Profiling Substrate Peptides & Profiling Services Large selection of cancer associated peptide substrates for sirtuins, kinases, acetyltransferases and more. Learn about our profiling services with your samples! Epigenetics Histone Code Tools Ready-to-use post-translationally modified H1, H2A, H2B, H3 and H4 peptides, high content peptide arrays and ELISA services.

5 Selected References Prognostic Impact of High Levels of Circulating Plasmacytoid Dendritic Cells in Breast Cancer Bailur et al., Journal of Translational Medicine (2016) PMID: Low Dose Gemcitabine-loaded Lipid Nanocapsules Target Monocytic Myeloid-derived Suppressor Cells and Potentiate Cancer Immunotherapy Sasso et al., Biomaterials (2016) Poxvirus-based Active Immunotherapy Synergizes With CTLA-4 Blockade to Increase Survival in a Murine Tumor Model by Im proving the Magnitude and Quality of Cytotoxic T Cells Foy et al., Cancer Immunol Immunother. (2016) PMID: How Frequently Are Predicted Peptides Actually Recognized by CD8 Cells? Moldovan et al., Cancer Immunol Immunother. (2016) PMID: Expression of DAI by an Oncolytic Vaccinia Virus Boosts the Immunogenicity of the Virus and Enhances Antitum or Immunity Hirvinen et al., Molecular Therapy (2016) RNA Vaccination Therapy: Advances in an Emerging Field Thielemans et al., Journal of Immunology Research (2016) I have been collaborating with JPT for several years. Their unique peptide library technologies and knowledge of specific peptide requirements for T cell assays made them a valuable, long-term partner in our efforts to develop novel adoptive immunotherapy approaches to prevent and treat viral infections post-transplant as well as for the treatment of virus and non virus-associated malignancies. Furthermore, their reagents allow us to precisely monitor and track specific T cell populations post-infusion. Ann Leen, PhD, Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, USA We utilize customized 15-mer PepMix Peptide Pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines. Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service. JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations. Benedetto Farsaci, PhD, National Cancer Institute, NIH, Bethesda, MD, USA

6 About JPT JPT Peptide Technologies is a DIN ISO 9001:2015 certified and GCLP compliant integrated company providing inno vative peptide based products and services focusing on: Immune & cell therapy development Deep (neo-)epitope discovery & qualification Monitoring of humoral & cellular immune responses Vaccine target identification Seromarker discovery Visit us at: Please contact our support team for information, questions or comments at: peptide@jpt.com Graphical material: cancer cell istock.com /Eraxion. Subject to changes. 08/2016 JPT Peptide Technologies peptide@jpt.com European Head Office T F USA/Canada T F